Tim Smith

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November are provided.

The phase 3 OLYMPIA 1 study highlights the benefits among those with prurigo nodularis of targeting interleukin-31 signaling using nemolizumab.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

This analysis involved assessing rates of lifetime as well as prior 12-month treatment use for AUD, in addition to demographic and clinical characteristics linked to AUD treatment.

In this study, investigators described the safety and tolerability of BLV therapy following 48 weeks of therapy among those with CHD.

These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an assessment tool.

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.

The VISIBLE study's findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.